Why Are Ozempic, Wegovy and Mounjaro Lawsuits Claiming Rare Vision Loss?
Lawsuits claim GLP-1 drugs like Ozempic, Wegovy, and Mounjaro lack warnings for rare permanent vision loss (NAION), which manufacturers deny as meritless or as being under routine safety monitoring. While studies show mixed correlation and unproven causation, doctors stress heavy metabolic benefits and advise consulting physicians rather than stopping treatment unsupervised.
Dozens of personal injury lawsuits in the United States claim manufacturers failed to warn patients of rare vision loss linked to drugs like Ozempic, Wegovy, and Mounjaro, though clinical studies have not proven direct causation.
Lawsuits and Manufacturer Response
- The Claims: Plaintiffs allege inadequate warning regarding nonarteritic anterior ischemic optic neuropathy (NAION), often described as an "eye stroke", reports ABC News.
- Novo Nordisk (Ozempic, Wegovy): Stated the US lawsuits are "without merit", defending the safety profile while noting readiness to act if emerging data requires regulatory alignment.
- Eli Lilly (Mounjaro, Zepbound): Emphasised that patient safety is top priority, routine monitoring and regulatory reporting are active, and ophthalmic data remains under review. Ozempic, Wegovy May Help Mental Health, Substance Disorders.
Why Patients Are Suing Over Vision Risks on Ozempic, Wegovy and Mounjaro
Clinical Understanding of NAION
- Definition: Dr John Chen of the Mayo Clinic describes NAION as acute optic neuropathy in patients over 50 caused by insufficient blood flow to the optic nerve, typically resulting in sudden, painless, permanent vision loss without specific treatment.
- Risk Factors: Dr Raj Maturi of the Midwest Eye Institute notes that diabetes (independent of GLP-1 use), nocturnal low blood pressure, or a small optic nerve cup elevate baseline risk.
- Regulatory Status: The FDA does not mandate NAION-specific warnings, though its Sentinel Initiative evaluates ongoing data. Agencies like the European Medicines Agency (EMA) and Australia's TGA treat rare NAION risk as a noted label consideration.
What the Research Demonstrates
- The 2024 Signal: A single Boston health system study suggested a potential association in type 2 diabetes patients using semaglutide.
- Mixed Follow-ups: Larger subsequent studies yielded mixed findings, establishing low-magnitude risk where correlation appears disputed or unproven.
- Clinical Balance: Cardiovascular, diabetic, and weight-management benefits from GLP-1 receptor agonists remain well validated.
Guidance for Patients
- Do Not Stop Medication Unsupervised: Physicians stress that untreated diabetes and obesity carry severe, proven systemic and ocular risks.
- Consult Providers: Discuss individual risk factors (such as prior NAION in one eye) with primary care physicians or ophthalmologists, and seek immediate evaluation for sudden painless vision changes. As Ozempic Use Grows, Lesser-known Risks Emerge.
As ongoing litigation and regulatory reviews progress, health agencies continue to emphasise balanced clinical decision-making. Patients weighing treatment options should consult healthcare providers regarding individual risk profiles, symptom monitoring, and the foundational importance of managing underlying metabolic conditions.
(The above story first appeared on LatestLY on Sep 22, 2026 08:57 AM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).